Ubs Group Ag Belite Bio, Inc Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Belite Bio, Inc stock. As of the latest transaction made, Ubs Group Ag holds 2,358 shares of BLTE stock, worth $182,509. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,358
Previous 551
327.95%
Holding current value
$182,509
Previous $36,000
277.78%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BLTE
# of Institutions
18Shares Held
76.4KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.2KShares$1.56 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA12.9KShares$995,6730.0% of portfolio
-
Marshall Wace, LLP London, X09.49KShares$734,2160.0% of portfolio
-
Jpmorgan Chase & CO New York, NY8.16KShares$631,7380.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il7.46KShares$577,0940.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.92B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...